Request Demo
Last update 07 May 2026
TQ-B3234
Last update 07 May 2026
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms TQ B3234 |
Target |
Action inhibitors |
Mechanism MEK1 inhibitors(Dual specificity mitogen-activated protein kinase kinase 1 inhibitors), MEK2 inhibitors(Dual specificity mitogen-activated protein kinase kinase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (China), Special Review Project (China) |
Login to view timeline
Related
3
Clinical Trials associated with TQ-B3234NCT07407803
Randomized, Double-Blind, Parallel-Controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of TQ-B3234 Capsules Versus Placebo in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas
NCT05107037
A Phase I Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of TQ-B3234 Capsules in Chinese Patients With Type I Neurofibromatosis (Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors)
NCT02996838
Phase I Study of Tolerance and Pharmacokinetics of TQ-B3234 in Patients With Advanced Cancer
100 Clinical Results associated with TQ-B3234
Login to view more data
100 Translational Medicine associated with TQ-B3234
Login to view more data
100 Patents (Medical) associated with TQ-B3234
Login to view more data
100 Deals associated with TQ-B3234
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| NF1 mutant Plexiform Neurofibroma | Phase 3 | China | 20 Mar 2026 | |
| NF1 mutant Plexiform Neurofibroma | Phase 3 | China | 20 Mar 2026 | |
| Neurofibrosarcoma | Phase 1 | China | 01 Nov 2021 | |
| Neurofibromatosis 1 | Phase 1 | China | 11 Oct 2021 | |
| Advanced cancer | Phase 1 | China | 27 Dec 2016 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 31 | wcuwjhiiqn(bvjplcqdtp) = eyzcdpsldc gtmgvwpxbw (bewoimewtw ) View more | Positive | 17 Oct 2025 | |||
akgcyduszs(rjfejajqum) = brzawuwscd njpsuwrnie (jfnbfaawxp ) View more | |||||||
NCT05107037 (ASCO2025) Manual  | Phase 1 | 40 | ngchdpwopf(lyxyyfjyrz) = One patient, a cNF case, experienced, in the form of G3 diarrhea (16.7%) at the 100 mg dose during the dose-escalation phase. kizujikvgn (eqspcfzwku ) View more | Positive | 28 May 2025 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free